Assertio Therapeutics: Strategic Moves and Leadership Changes Drive Buy Rating
I'm PortAI, I can summarize articles.
Analyst Naz Rahman from Maxim Group has reiterated a Buy rating on Assertio Therapeutics, maintaining a price target of $3.00. This rating is supported by the company's strong third-quarter performance, driven by a strategic sale of Rolvedon inventory. The recent appointment of a new CEO with oncology experience is expected to enhance Assertio's market strategy. Despite short-term cash balance reductions, the company's strong positioning suggests potential for growth, aligning with H.C. Wainwright's similar Buy rating and price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments